EKF Diagnostics has announced that its Quo-Test and Quo-Lab point-of-care HbA1c analysers have been positively assessed in a scientific poster presented at the World Diabetes Congress.

Dr Stephen Luzio, associate professor at the college of medicine at Swansea University, has discussed the performance of the devices at the International Diabetes Federation event after the university conducted an analytical trial of the systems.

“EKF Diagnostics' Quo-Test and Quo-Lab point-of-care HbA1c analysers have received recommendations following an analysis presented at the World Diabetes Congress.“

It was found that the EKF analysers offered a similar performance to a lab-based high-performance liquid chromatography (HPLC) method, with results generated immediately in the clinical setting.

The poster concluded: "Use of the Quo-Test and Quo-Lab HbA1c POCT analysers provides a rapid, accurate and reproducible method of determination of HbA1c, with results comparable to an established laboratory HPLC method."

HbA1c, also known as glycated haemoglobin, is widely used as a means of monitoring diabetes control and has also recently been recommended for use as a method of diabetes diagnosis.

Quo-Test and Quo-Lab also demonstrated their strong performance in an analysis carried out by Imcarmed, results from which were presented last month.